Skip to content
Study details
Enrolling now

Cannabidiol (CBD) in Adults With ASD

Johns Hopkins University
NCT IDNCT05015439ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

40

Study length

about 3.7 years

Ages

18+

Locations

1 site in MD

About this study

Researchers are testing whether cannabidiol (CBD), a treatment, can help adults with autism spectrum disorder (ASD) who have anxiety, mood problems, sleep issues, and agitation. The trial will last 14 weeks, with participants receiving either CBD or a placebo pill for six weeks each, followed by two weeks without medication. Participants will be asked about their symptoms and daily functioning during it.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Cannabidiol
  • 2.Take Placebo
PhasePhase 1
DrugCannabidiol
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

cannabidiol

Drug routes

oral (Oral Solution)

Endpoints

Secondary: Change in Anxiety as assessed by the Hamilton Anxiety Rating Scale, Change in Mini Mental State Examination (MMSE), Change in Waisman Activities of Daily Living scale

Body systems

Psychiatry / Mental Health